Preparation of  188 Re-Labetalol as a β 1 -Adrenoceptor for Use in Nuclear Medicine

F. A. Marzook; H. E. Ramadan; H. M. Talaat

doi:10.1134/S1066362219020188

Preparation of ¹⁸⁸Re-Labetalol as a β₁-Adrenoceptor for Use in Nuclear Medicine

Authors: Marzook F.A.¹, Ramadan H.E.², Talaat H.M.¹
Affiliations:
1. Labeled Compounds Department, Hot Laboratories Center
2. Radioactive Isotopes and Generator Department, Hot Laboratories Center
Issue: Vol 61, No 2 (2019)
Pages: 238-243
Section: Article
URL: https://ogarev-online.ru/1066-3622/article/view/225110
DOI: https://doi.org/10.1134/S1066362219020188
ID: 225110

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Labetalol was labeled with ¹⁸⁸Re. The reaction conditions (amounts of stannous chloride and substrate, pH, time) were optimized, and the radiochemical yield as high as 95 ± 0.4% was reached. Biodistribution in mice was studied. ¹⁸⁸Re-Labetalol showed excellent initial heart uptake and good retention. The heart/liver ratios were 5.16, 2.70, and 2.15 at 30, 60, and 120 min post injection, respectively.